AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30579407 — intervention group
Group type: EXPERIMENTAL
Intervention: Delirium/possible delirium detection
Number of subjects: 159
Study 30579407 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-delirium days classification
Number of subjects: 159
Study 30580112 — intervention group
Group type: EXPERIMENTAL
Intervention: vemurafenib
Number of subjects: 3219
Study 30580112 — intervention group
Group type: EXPERIMENTAL
Intervention: vemurafenib plus cobimetinib
Number of subjects: 3219
Study 30580128 — intervention group
Group type: EXPERIMENTAL
Intervention: MAGGIC risk score
Number of subjects: 6859
Study 30580128 — intervention group
Group type: COMPARATOR
Intervention: Low-risk group (probability <14%)
Number of subjects: 6859
Study 30580128 — intervention group
Group type: COMPARATOR
Intervention: High-risk group (probability >56%)
Number of subjects: 6859
Study 30580128 — intervention group
Group type: COMPARATOR
Intervention: Low-risk group (N = 61 dead, 743 alive)
Number of subjects: 6859
Study 30580128 — intervention group
Group type: COMPARATOR
Intervention: High-risk group (N = 210 alive, 375 dead)
Number of subjects: 6859
Study 30580192 — intervention group
Group type: EXPERIMENTAL
Intervention: Home sleep apnea testing (HSAT)
Number of subjects: 236
Study 30580256 — intervention group
Group type: EXPERIMENTAL
Intervention: STarT Back Tool (SBT) risk group stratification
Number of subjects: 329
Study 30580256 — intervention group
Group type: COMPARATOR
Intervention: High risk group (SBT)
Number of subjects: 329
Study 30580256 — intervention group
Group type: EXPERIMENTAL
Intervention: SBT
Number of subjects: 329
Study 30580418 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular repositioning device (MRD) therapy
Number of subjects: 0
Study 30580559 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary atherosclerosis imaging
Number of subjects: 0
Study 30580717 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal flow (43 subjects)
Number of subjects: 72
Study 30580717 — intervention group
Group type: EXPERIMENTAL
Intervention: Low/borderline flow (23 subjects: 16 low flow, 7 borderline flow)
Number of subjects: 72
Study 30580717 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoperfusion symptoms
Number of subjects: 72
Study 30580717 — intervention group
Group type: COMPARATOR
Intervention: Flow status
Number of subjects: 72
Study 30580723 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy + TOBT
Number of subjects: 89
Study 30580723 — intervention group
Group type: COMPARATOR
Intervention: General health education + TOBT
Number of subjects: 89
Study 30580852 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet therapy
Number of subjects: 1388
Study 30580852 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulant therapy (mainly vitamin K antagonist)
Number of subjects: 1388
Study 30580852 — intervention group
Group type: EXPERIMENTAL
Intervention: All-cause mortality
Number of subjects: 1388
Study 30580852 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke/systemic embolism and major bleeding rates
Number of subjects: 1388
Study 30580992 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Mellitus (DM)
Number of subjects: 1296
Study 30580992 — intervention group
Group type: COMPARATOR
Intervention: Normal glycemic status
Number of subjects: 1296
Study 30580992 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-diabetes (pre-DM)
Number of subjects: 1296
Study 30581606 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludrocortisone (0.4 mg per day for 7 days)
Number of subjects: 30
Study 30581606 — intervention group
Group type: COMPARATOR
Intervention: Low- and high-sodium diet cycles (reference test)
Number of subjects: 30
Study 30581662 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise intervention (2 to 3 sessions per week for 12 weeks)
Number of subjects: 68
Study 30581662 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group (CG)
Number of subjects: 68
Study 30581893 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency apheresis (≥20 donations in one year)
Number of subjects: 0
Study 30582166 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative antibiotic use (mean 27.8 ± 22.7 days out of 90 days prior to ESS)
Number of subjects: 271
Study 30582166 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased preoperative antibiotic use
Number of subjects: 271
Study 30582166 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative antibiotic use
Number of subjects: 271
Study 30582431 — intervention group
Group type: EXPERIMENTAL
Intervention: Full code management group
Number of subjects: 109
Study 30582431 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU trial (IT) group
Number of subjects: 109
Study 30582431 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 109
Study 30582669 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-dimensional magnetic resonance elastography (3D-MRE) with shear stiffness at 60 Hz, damping ratio at 40 Hz, and MRI-PDFF
Number of subjects: 175
Study 30582928 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI) for fetal weight estimation
Number of subjects: 270
Study 30582928 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound imaging for fetal weight estimation
Number of subjects: 270
Study 30583256 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine (50-100 mg/day)
Number of subjects: 36
Study 30583899 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise program (SEP), three times per week for 12 weeks
Number of subjects: 109
Study 30583927 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG-PET scans at baseline and during CRT
Number of subjects: 21
Study 30583934 — intervention group
Group type: EXPERIMENTAL
Intervention: Early infancy (sweat chloride concentration)
Number of subjects: 59
Study 30583934 — intervention group
Group type: EXPERIMENTAL
Intervention: Late infancy (sweat chloride concentration)
Number of subjects: 59
Study 30583965 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-hydroxyvitamin D (25OHD) and 1,25-dihydroxyvitamin D (1,25(OH)
Number of subjects: 92
Study 30583995 — intervention group
Group type: EXPERIMENTAL
Intervention: AIP cases
Number of subjects: 50
Study 30584308 — intervention group
Group type: EXPERIMENTAL
Intervention: Tigecycline (initial dose 100 mg, then 50 mg q12h)
Number of subjects: 470
Study 30584308 — intervention group
Group type: COMPARATOR
Intervention: Imipenem/cilastatin (500 mg/500 mg or adjusted for renal dysfunction, q6h)
Number of subjects: 470
Study 30584308 — intervention group
Group type: EXPERIMENTAL
Intervention: Tigecycline
Number of subjects: 470
Study 30584308 — intervention group
Group type: COMPARATOR
Intervention: Imipenem/cilastatin
Number of subjects: 470
Study 30584317 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib
Number of subjects: 0
Study 30584317 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine/cisplatin
Number of subjects: 0
Study 30584583 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized Glycopyrrolate
Number of subjects: 0
Study 30585255 — intervention group
Group type: EXPERIMENTAL
Intervention: SAR405838 200 mg QD plus pimasertib 45 mg BID
Number of subjects: 26
Study 30585255 — intervention group
Group type: EXPERIMENTAL
Intervention: SAR405838 200 mg QD plus pimasertib 60 mg QD or 45 mg BID
Number of subjects: 26
Study 30585255 — intervention group
Group type: EXPERIMENTAL
Intervention: SAR405838 and pimasertib combined
Number of subjects: 26
Study 30585690 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 14
Study 30585698 — intervention group
Group type: EXPERIMENTAL
Intervention: One-legged high-intensity interval training (HIIT)
Number of subjects: 20
Study 30585770 — intervention group
Group type: EXPERIMENTAL
Intervention: MiniMed 670G system with SmartGuard technology in Auto Mode for 3 months
Number of subjects: 105
Study 30586079 — intervention group
Group type: EXPERIMENTAL
Intervention: Updated biopsychosocial model of successful aging with HIV
Number of subjects: 0
Study 30586083 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training interventions
Number of subjects: 13
Study 30586316 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib administered once weekly at 300 mg
Number of subjects: 69
Study 30586316 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib administered once every 2 weeks at 700 mg
Number of subjects: 69
Study 30586316 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib (both dosing schedules)
Number of subjects: 69
Study 30586316 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib (once every 2 weeks at 700 mg)
Number of subjects: 69
Study 30586363 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower respiratory tract (LRT) samples
Number of subjects: 115
Study 30586363 — intervention group
Group type: COMPARATOR
Intervention: Nasal samples
Number of subjects: 115
Study 30586692 — intervention group
Group type: EXPERIMENTAL
Intervention: Idarucizumab (5-g dose administered as 2 bolus infusions of 2.5 g no more than 15 minutes apart)
Number of subjects: 137
Study 30586692 — intervention group
Group type: EXPERIMENTAL
Intervention: Idarucizumab
Number of subjects: 137
Study 30586699 — intervention group
Group type: EXPERIMENTAL
Intervention: FFR derived from routine coronary angiography
Number of subjects: 301
Study 30586699 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary pressure wire and hyperemic stimulus
Number of subjects: 301
Study 30586721 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraaortic Balloon Pump (IABP)
Number of subjects: 600
Study 30586721 — intervention group
Group type: COMPARATOR
Intervention: Control group (no IABP)
Number of subjects: 600
Study 30586731 — intervention group
Group type: COMPARATOR
Intervention: USPIO enhancement in ballooning left ventricular myocardial segments
Number of subjects: 55
Study 30586731 — intervention group
Group type: COMPARATOR
Intervention: USPIO enhancement in nonballooning left ventricular myocardial segments
Number of subjects: 55
Study 30586731 — intervention group
Group type: COMPARATOR
Intervention: Serum interleukin-6 concentrations
Number of subjects: 55
Study 30586731 — intervention group
Group type: COMPARATOR
Intervention: Serum chemokine (C-X-C motif) ligand 1 concentrations
Number of subjects: 55
Study 30586733 — intervention group
Group type: EXPERIMENTAL
Intervention: Familial hypercholesterolemia mutation
Number of subjects: 2081
Study 30586733 — intervention group
Group type: EXPERIMENTAL
Intervention: High polygenic score
Number of subjects: 2081
Study 30586733 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean untreated low-density lipoprotein cholesterol
Number of subjects: 2081
Study 30586734 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive cardiac radioablation (25 Gy single fraction)
Number of subjects: 19
Study 30586734 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive cardiac radioablation
Number of subjects: 19
Study 30586740 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation patients over 12 months
Number of subjects: 52014
Study 30586740 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation patients in the first month
Number of subjects: 52014
Study 30586740 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive model for 1-month risk of death
Number of subjects: 52014
Study 30586745 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg once daily
Number of subjects: 132
Study 30586745 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study 30586748 — intervention group
Group type: EXPERIMENTAL
Intervention: EHMRG7
Number of subjects: 1983
Study 30586748 — intervention group
Group type: EXPERIMENTAL
Intervention: EHMRG7 combined with physician estimates
Number of subjects: 1983
Study 30586748 — intervention group
Group type: EXPERIMENTAL
Intervention: EHMRG30-ST
Number of subjects: 1983
Study 30586748 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician-estimated risk combined with EHMRG30-ST
Number of subjects: 1983
Study 30586748 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality rates at 7 days
Number of subjects: 1983
Study 30586748 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality rates at 30 days
Number of subjects: 1983
Study 30586749 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting Full-Cycle Ratio (RFR)
Number of subjects: 435
Study 30586749 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic Pressure Ratio (dPR)
Number of subjects: 435
Study 30586749 — intervention group
Group type: COMPARATOR
Intervention: Instantaneous Wave-Free Ratio (iFR)
Number of subjects: 435
Study 30586749 — intervention group
Group type: EXPERIMENTAL
Intervention: All resting pressure-derived physiological indexes (iFR, RFR, dPR)
Number of subjects: 435
Study 30586751 — intervention group
Group type: EXPERIMENTAL
Intervention: PCDT with anticoagulation
Number of subjects: 391
Study 30587228 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankylosing spondylitis (AS) patients
Number of subjects: 210
Study 30587230 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) program for 10 weeks
Number of subjects: 21
Study 30587248 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (61-84%)
Number of subjects: 15284
Study 30587248 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (24%-61.8%)
Number of subjects: 15284
Study 30587248 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticoids (16.7-42.1%)
Number of subjects: 15284
Study 30587418 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-MPI
Number of subjects: 97
Study 30587418 — intervention group
Group type: COMPARATOR
Intervention: SPECT
Number of subjects: 97
Study 30587541 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher SES
Number of subjects: 623
Study 30587911 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifocal group (bilateral bifocal implantation)
Number of subjects: 0
Study 30587911 — intervention group
Group type: EXPERIMENTAL
Intervention: Trifocal group (bilateral trifocal implantation)
Number of subjects: 0
Study 30587911 — intervention group
Group type: COMPARATOR
Intervention: Control group (bilateral pseudophakic monofocal implantation)
Number of subjects: 0
Study 30587935 — intervention group
Group type: EXPERIMENTAL
Intervention: Elbasvir/grazoprevir (EBR/GZR)
Number of subjects: 255
Study 30587935 — intervention group
Group type: COMPARATOR
Intervention: Sofosbuvir with pegylated interferon and ribavirin (SOF/PR)
Number of subjects: 255
Study 30587957 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease Awareness in COPD Questionnaire (DACQ)
Number of subjects: 0
Study 30587996 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive brexpiprazole 2-3 mg/day
Number of subjects: 1171
Study 30587996 — intervention group
Group type: COMPARATOR
Intervention: Placebo (adjunct to ADT)
Number of subjects: 1171
Study 30588103 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary surgery with postoperative intensity-modulated radiotherapy (IMRT) delivering 65-70 Gy to CTV1 and 50-55 Gy to CTV2.
Number of subjects: 33
Study 30588886 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic oral anticoagulant therapy (OACb)
Number of subjects: 10568
Study 30589299 — intervention group
Group type: EXPERIMENTAL
Intervention: Socioaffective mental training
Number of subjects: 0
Study 30589299 — intervention group
Group type: EXPERIMENTAL
Intervention: Sociocognitive mental training
Number of subjects: 0
Study 30589299 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 30589493 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-1 antitrypsin deficiency with neonatal cholestasis
Number of subjects: 153
Study 30589493 — intervention group
Group type: COMPARATOR
Intervention: Alpha-1 antitrypsin deficiency without neonatal cholestasis
Number of subjects: 153
Study 30589495 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocoagulable TEG at baseline
Number of subjects: 243
Study 30589495 — intervention group
Group type: EXPERIMENTAL
Intervention: Coagulation Index
Number of subjects: 243
Study 30589495 — intervention group
Group type: EXPERIMENTAL
Intervention: Clot lysis
Number of subjects: 243
Study 30589495 — intervention group
Group type: EXPERIMENTAL
Intervention: Low protein C < 30%
Number of subjects: 243
Study 30589495 — intervention group
Group type: EXPERIMENTAL
Intervention: ATIII
Number of subjects: 243
Study 30589495 — intervention group
Group type: EXPERIMENTAL
Intervention: tPA
Number of subjects: 243
Study 30589495 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein C activity <30%
Number of subjects: 243
Study 30589495 — intervention group
Group type: EXPERIMENTAL
Intervention: tPA >20 ng/mL
Number of subjects: 243
Study 30589773 — intervention group
Group type: EXPERIMENTAL
Intervention: Porcine-derived acellular peritoneal matrix
Number of subjects: 25
Study 30589809 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve transfers
Number of subjects: 0
Study 30589964 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate add-on therapy
Number of subjects: 0
Study 30589964 — intervention group
Group type: COMPARATOR
Intervention: UDCA alone
Number of subjects: 0
Study 30590416 — intervention group
Group type: EXPERIMENTAL
Intervention: Transannular mitral bridge implantation
Number of subjects: 34
Study 30590505 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian hierarchical model for network inference
Number of subjects: 0
Study 30590564 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting heart rate (RHR) categories: <60 bpm, 60≤65 bpm, 65≤70 bpm, 70≤75 bpm, 75≤80 bpm, ≥80 bpm
Number of subjects: 30937
Study 30590564 — intervention group
Group type: EXPERIMENTAL
Intervention: RHR ≥80 bpm
Number of subjects: 30937
Study 30590564 — intervention group
Group type: EXPERIMENTAL
Intervention: RHR categories
Number of subjects: 30937
Study 30590564 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean RHR above 75-80 bpm
Number of subjects: 30937
Study 30590569 — intervention group
Group type: EXPERIMENTAL
Intervention: Saturated fat ingestion
Number of subjects: 38
Study 30590576 — intervention group
Group type: EXPERIMENTAL
Intervention: Malaria infection before gestational age of 15 weeks
Number of subjects: 138
Study 30590587 — intervention group
Group type: EXPERIMENTAL
Intervention: Prepregnancy free androgen index
Number of subjects: 2768
Study 30590587 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting glucose
Number of subjects: 2768
Study 30590587 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone
Number of subjects: 2768
Study 30590587 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting insulin
Number of subjects: 2768
Study 30590587 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonspecific features to PCOS
Number of subjects: 2768
Study 30590586 — intervention group
Group type: EXPERIMENTAL
Intervention: T90 > 12 min
Number of subjects: 2840
Study 30590586 — intervention group
Group type: EXPERIMENTAL
Intervention: T90
Number of subjects: 2840
Study 30590586 — intervention group
Group type: EXPERIMENTAL
Intervention: ODI
Number of subjects: 2840
Study 30590586 — intervention group
Group type: EXPERIMENTAL
Intervention: T90desaturation and T90non-specific
Number of subjects: 2840
Study 30590596 — intervention group
Group type: EXPERIMENTAL
Intervention: Phylloquinone repletion (∼500 µg phylloquinone/d)
Number of subjects: 63
Study 30590596 — intervention group
Group type: EXPERIMENTAL
Intervention: Phylloquinone depletion (∼10 µg phylloquinone/d)
Number of subjects: 63
Study 30590596 — intervention group
Group type: EXPERIMENTAL
Intervention: Deuterated phylloquinone-rich collard greens (2H-phylloquinone) consumed on the 23rd day of each diet phase
Number of subjects: 63
Study 30591285 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-medications
Number of subjects: 1397
Study 30591285 — intervention group
Group type: COMPARATOR
Intervention: Immunosuppressants
Number of subjects: 1397
Study 30591290 — intervention group
Group type: EXPERIMENTAL
Intervention: INCRAFT AAA endograft
Number of subjects: 60
Study 30591411 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance exercise
Number of subjects: 0
Study 30591411 — intervention group
Group type: EXPERIMENTAL
Intervention: Drp1 signaling
Number of subjects: 0
Study 30591548 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA 100 mg/day orally in combination with an aromatase inhibitor (AI)
Number of subjects: 12
Study 30591548 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA 100 mg/day orally
Number of subjects: 12
Study 30591982 — intervention group
Group type: EXPERIMENTAL
Intervention: Tarextumab 5 mg/kg weekly
Number of subjects: 42
Study 30591982 — intervention group
Group type: EXPERIMENTAL
Intervention: Tarextumab 10 mg/kg every other week
Number of subjects: 42
Study 30591982 — intervention group
Group type: EXPERIMENTAL
Intervention: Tarextumab 7.5 mg/kg every three weeks
Number of subjects: 42
Study 30591982 — intervention group
Group type: EXPERIMENTAL
Intervention: Tarextumab 2.5 mg/kg weekly
Number of subjects: 42
Study 30591982 — intervention group
Group type: EXPERIMENTAL
Intervention: Tarextumab 7.5 mg/kg every other week
Number of subjects: 42
Study 30591982 — intervention group
Group type: EXPERIMENTAL
Intervention: Tarextumab at doses <2.5 mg weekly and 7.5 mg/kg every other and every three weeks
Number of subjects: 42
Study 30591982 — intervention group
Group type: EXPERIMENTAL
Intervention: Tarextumab
Number of subjects: 42
Study 30592353 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy with defibrillator (CRT-D)
Number of subjects: 1274
Study 30592353 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT-D-induced reverse remodelling
Number of subjects: 1274
Study 30592353 — intervention group
Group type: COMPARATOR
Intervention: Implantable cardioverter defibrillator (ICD)
Number of subjects: 1274
Study 30592431 — intervention group
Group type: EXPERIMENTAL
Intervention: Karaduman Chewing Performance Scale (KCPS)
Number of subjects: 119
Study 30592431 — intervention group
Group type: EXPERIMENTAL
Intervention: Segmental Assessment of Trunk Control (SATCo)
Number of subjects: 119
Study 30593271 — intervention group
Group type: EXPERIMENTAL
Intervention: Presumed malaria incidence
Number of subjects: 2723
Study 30593271 — intervention group
Group type: EXPERIMENTAL
Intervention: Diarrhea incidence
Number of subjects: 2723
Study 30593271 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute respiratory infections (ARI) incidence
Number of subjects: 2723
Study 30593513 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib (first-line treatment for patients with CNS metastasis at diagnosis)
Number of subjects: 977
Study 30593513 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab (first-line treatment for patients with CNS metastasis at diagnosis)
Number of subjects: 977